BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25240937)

  • 1. Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    J Transl Med; 2014 Sep; 12():265. PubMed ID: 25240937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.
    Kumai T; Ohkuri T; Nagato T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Celis E; Harabuchi Y; Kobayashi H
    Sci Rep; 2015 Nov; 5():16280. PubMed ID: 26538233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Toyoda M; Takahashi K; Yamamoto T; Masuyama K
    Cancer Sci; 2012 Jun; 103(6):976-83. PubMed ID: 22360618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is EGFR really a therapeutic target in head and neck cancers?
    Agarwal V; Subash A; Nayar RC; Rao V
    J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
    Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
    Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
    Tsien CI; Nyati MK; Ahsan A; Ramanand SG; Chepeha DB; Worden FP; Helman JI; D'Silva N; Bradford CR; Wolf GT; Lawrence TS; Eisbruch A
    Head Neck; 2013 Sep; 35(9):1323-30. PubMed ID: 22907806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
    Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
    Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
    Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
    Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
    Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma.
    Schuler PJ; Boeckers P; Engers R; Boelke E; Bas M; Greve J; Dumitru CA; Lehnerdt GF; Ferris RL; Andrade Filho PA; Brandau S; Lang S; Whiteside TL; Hoffmann TK
    J Transl Med; 2011 Oct; 9():168. PubMed ID: 21970318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.